Search - tctmd.com

Displaying 201 - 220 of 274

Sort: Relevancy | Date

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

某些患者 TAVR 后认知改善，但也有些下降，导致很难有统一指南

Shelley Wood

September 29, 2016

News Daily News

La Cognición Post-TAVR Mejora en Algunos Pacientes y Desciende en Otros y son Pocas las Señales Orientativas

Shelley Wood

September 29, 2016

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

Shelley Wood

September 22, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

L.A. McKeown

August 24, 2016

News Daily News

Medtronic Warns of Vascular Trauma, Some Resulting in Death, With CoreValve’s EnVeo R Delivery Catheter

Michael O'Riordan

August 18, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

Presentation TVT 2016

Evolution From a TAVR Program to an Aortic Valve Center of Excellence

Presenter: A. Pieter Kappetein

June 18, 2016

News Conference News TVT 2016

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Michael O'Riordan

June 18, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

News Features

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Caitlin E. Cox

June 17, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

News Daily News

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

Michael O'Riordan

June 07, 2016

News Daily News

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

Michael O'Riordan

June 07, 2016

News Daily News

Evolution of TAVR in Denmark May Have Implications for Other Countries

L.A. McKeown

June 06, 2016

News Conference News EuroPCR 2016

Studies Highlight Permanent Pacemaker Rates Among New-Generation TAVR Devices

Michael O'Riordan

May 23, 2016

Advertisement

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

某些患者 TAVR 后认知改善，但也有些下降，导致很难有统一指南

La Cognición Post-TAVR Mejora en Algunos Pacientes y Desciende en Otros y son Pocas las Señales Orientativas

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

Medtronic Warns of Vascular Trauma, Some Resulting in Death, With CoreValve’s EnVeo R Delivery Catheter

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Evolution From a TAVR Program to an Aortic Valve Center of Excellence

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

What TAVR Needs Next . . . and What It’s Getting

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

Evolution of TAVR in Denmark May Have Implications for Other Countries

Studies Highlight Permanent Pacemaker Rates Among New-Generation TAVR Devices

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content